Auxilium Pharmaceuticals Inc. will focus its initial marketing efforts of Xiaflex (collagenase clostridium histolyticum) for Peyronie’s disease patients to the small population of urologists who currently treat the disease invasively, before branching out to target the majority of urologists.
The Dec. 6 approval of Auxilium’s sBLA makes Xiaflex the first medicine and non-surgical option to treat men with the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?